1Ross RK, Yuan JM, Yu MC, et al. Vninary aflatoxin biomakers and risk of hepatocellulor carcinoma[J]. Lancet, 1992, 399. 943 - 946.
2Kuang SY, Fang X, Lu BX, et al. Alatoxin-albimin adducts and risk for hepatocellularr carcinoma in residents of Qidong, People's Republic of China[J ]. Proc Am Assoc Cancer Res, 1996, 37:252.
3Gerald N, Wogan. Impacts of chemicals on liver cancer risk[C].Seminars in Cancer biology, 2000, 10:201 - 210.
4Egner PA, Gange SJ, Dolan PM, et al. Level of aflatoxin-albumin biomorkers in rat plasma are modulated by both long-term and transient interventions with oltipraz [J ]. Carcinogenesis, 1995, 16:1769- 1774.
5Wang JS, Shen XN, He X, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China[J ]. J Natl Cancer Inst, 1999, 91 (4): 347 -354.
6Bailey EA, Iyer RSD, Stone MP, et al. Mutational properties of the primary aflatoxin B1-DNA adduct [ J ]. Proc Natl Acad Sci USA,1996, 93:1535 - 1539.
8Smela ME, Hamm ML, Henderson PT. The aflatoxin B(1 ) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma[ J ]. Proc Natl Acad Sci USA, 2002, 99 (10): 6655 - 6660.
10R C Gupta, W K Lutz. Background DNA damage from endogenous and unavoidable expgenous exposure to geno-toxic carcinogens[J ].Mutat Res, 1999, in press.
